Dr. Guido Zaman is Managing Director and founder of Oncolines. He co-founded Netherlands Translational Research Center B.V. (NTRC) in 2011, where, together with colleagues he successfully set up and developed NTRC’s Precision Medicine Services (now Oncolines) and several small molecule drug discovery projects for protein kinases and tryptophan metabolizing enzymes (IDO1 and TDO). The TTK kinase project was translated from concept to the Investigational New Drug BAL 0891 (NTRC 0891). Guido worked as an investigator at the Netherlands Cancer Institute in Amsterdam, before joining Organon/MSD, where he worked as a Senior Director in Molecular Pharmacology and led multidisciplinary project teams on protein kinases, G protein-coupled receptors and assay development for high-throughput screening. Guido published more than 80 articles in scientific journals and is an inventor on eight patents.